Cross-Sector entity
Weiss Ratings is the most frequent co-covered peer, appearing in 5 of the 5 tracked stories. pharma accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder. Citadel Advisors LLC appears in 5 tracked Cross-Sector stories published from August 12, 2026 through August 13, 2026.
5 verified stories tracked
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 5 of the 5 tracked stories. pharma accounts for 2 of the 5 tracked stories, while 3 other categories carry the remainder. Citadel Advisors LLC appears in 5 tracked Cross-Sector stories published from August 12, 2026 through August 13, 2026. The tracked stories average 2 original sources each. 0% of these stories carry negative sentiment.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Citadel Advisors LLC. Shared-story counts are live from our verified record — not editorial picks.
Shares drop 1.8%
APYX traded as low as $4.34 and last at $4.38 on volume of 43,859 shares, 60% below average.
Weiss Ratings reiterates sell
Weiss Ratings reissued a sell (d-) rating on Apyx Medical shares.
Q1 earnings beat
Apyx Medical reported Q1 EPS of -$0.05 vs -$0.11 expected and revenue of $12.49M vs $10.53M expected.
Wall Street Zen downgrades APYX
Wall Street Zen lowered Apyx Medical from a buy rating to a hold rating.
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
Ensysce Biosciences short interest soared 619.9% to 364,278 shares as its stock trades at $0.30, while Focus Universal posted just $0.05M in quarterly revenue. The data highlights severe financial fragility across two small healthcare and device innovators.
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
Shares of Entera Bio slipped 0.6% to $1.54 on 78% below-average volume, but analysts remain deeply split: HC Wainwright reiterates buy while Weiss Ratings maintains a sell. The $9.00 consensus target implies roughly 484% upside for the $75.91M microcap biotech.
Source: dailypolitical.com · tickerreport.com
